相关实验视频

Updated: Aug 4, 2026

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

来自磁共振成像的参数,用于预测复发性质母细胞瘤中对regorafenib的反应

Matia Martucci¹, Andrea Maurizio Ferranti², Francesco Schimperna²

¹UOSD Neuroradiologia Diagnostica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy. matia.martucci@policlinicogemelli.it.

|May 29, 2023

概括

在治疗前通过MRI测量的最大相对脑血量 (rCBVmax) 可以预测复发性质母细胞瘤患者对regorafenib的反应. 较高的rCBVmax表明治疗结果更好,生存时间更长.

科学领域:

神经瘤学神经瘤学
放射学放射学是一门学科.
医疗成像医学成像

背景情况:

雷戈拉菲尼布是一种用于复发性质母细胞瘤 (rGB) 的多酶抑制剂.
它的生存益处可能很小,需要生物标志物来识别响应者.
预测成像生物标志物可以为RGB患者个性化治疗.

研究的目的:

评估磁共振成像 (MRI) 衍生的参数作为非侵入性生物标志物.
预测复发性质母细胞瘤 (rGB) 患者对雷戈拉费尼布的治疗反应.

主要方法:

20名rGB患者在诊断,复发和regorafenib治疗期间的随访期间接受了MRI.
评估的参数包括rCBVmax,ITSS,ADC值和瘤体积.
与治疗反应 (RANO标准),PFS和OS相关的成像生物标志物.

主要成果:

8/20患者在第一次随访时实现了稳定的疾病.
较高的基线rCBVmax与稳定的疾病相关 (p=0.04).
稳定的疾病患者表现出更长的PFS (p=0.02) 和OS (p=0.04).

结论:

基线rCBVmax可以作为rGB中的regorafenib反应的非侵入性成像生物标志物.
这一发现可能有助于为质母细胞瘤患者个性化治疗策略.
需要进一步验证以确认rCBVmax作为预测生物标志物.

关键词:

这是CBV的CBV.DSC-PWI 公司图像化生物标志物生物标志物质母细胞瘤的复发性雷戈拉费尼布的使用情况

更多相关视频

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

Translational Orthotopic Models of Glioblastoma Multiforme

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

相关概念视频

Magnetic Resonance Imaging

Magnetic Resonance Imaging

Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique based on a phenomenon of nuclear physics discovered in the 1930s, in which matter exposed to magnetic fields and radio waves was found to emit radio signals. In 1970, a physician and researcher named Raymond Damadian noticed that malignant (cancerous) tissue gave off different signals than normal body tissue. He applied for a patent for the first MRI scanning device in clinical use by the early 1980s. The early MRI...